VVOS — Vivos Therapeutics, Inc.

Vivos Therapeutics Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Increased by 70% year-over-year to $5.1 million, up from $3 million in Q1 2025, and a 34% increase from Q4 2025.
• Revenue Breakdown:
  • $2 million increase in sleep testing services.
  • $900,000 increase from Vivos treatment of OSA patients at two SCN locations.
  • Decline of $900,000 in appliance sales to VIP dentist customers, offset by a $500,000 increase in tooth positioner sales.
• Gross Profit: Increased by 103% to $3.1 million, with a gross margin improvement to 60% from 50% in Q1 2025.
• Expenses: General and administrative expenses rose to $9 million, primarily due to SCN operations and personnel costs.
• Net Cash Used in Operations: Increased to $6 million from $3.8 million in Q1 2025.
• Cash Position: $2.1 million in cash and cash equivalents as of March 31, 2026.

2. Strategic Updates and Business Highlights

• Acquisition Impact: The acquisition of the Sleep Center of Nevada (SCN) is showing positive results, with a significant increase in patient appointments (up 72% from Q4 2025) and treatment visits (up 43%).
• Operational Improvements: The company is expanding its facilities in Las Vegas to accommodate more patients and enhance service delivery.
• New Initiatives: Vivos is pursuing affiliations with medical specialty groups, expanding into insomnia and other sleep disorders, and launching a pediatric program based on successful clinical trials.

3. Forward Guidance and Outlook

• Revenue Growth: Management expects continued revenue growth in Q2 2026, driven by increased patient encounters and in-network insurance coverage.
• Profitability Goals: The company aims to achieve cash flow positive operations and is targeting net contribution margins approaching 50% by the end of 2026.
• Debt Restructuring: Plans are in place to restructure senior debt to alleviate cash service obligations and enhance stockholder equity.

4. Bad News, Challenges, or Points of Concern

• VIP Enrollment Decline: There were no new VIP enrollments in Q1, indicating a shift away from reliance on this revenue stream.
• Increased Costs: Higher operational costs related to SCN integration and staffing have impacted profitability despite revenue growth.
• Cash Flow Pressures: The company continues to experience cash flow challenges, necessitating additional financing to meet operational needs and comply with NASDAQ requirements.

5. Notable Q&A Insights

• Margin Improvement: Management indicated that margin improvements will ramp up over time, with expectations to reach steady-state operating levels by the end of 2026.
• Deferred Revenue: The remaining deferred revenue from VIP is around $100,000, which is expected to be fully recognized by year-end.
• Competitive Positioning: Vivos is aligning with a national firm for insurance contracts to enhance its competitive advantage and streamline operations across state lines.

In summary, Vivos Therapeutics is experiencing significant revenue growth driven by its strategic pivot towards sleep centers and enhanced service offerings. However, the company faces challenges related to cash flow, operational costs, and the transition away from its previous business model. Management remains optimistic about future growth and profitability.